AGTC to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced that its leadership team, including CEO Sue Washer and CFO Jon Lieber, will present virtually at the H.C. Wainwright Global Investment Conference from May 23 - 26, 2022. The presentation will be available on-demand starting May 24 at 7:00 a.m. ET.

AGTC is focused on developing gene therapies for rare diseases, particularly in ophthalmology. Their clinical trials, including X-linked retinitis pigmentosa and achromatopsia, aim to address significant unmet patient needs.

GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that Sue Washer, President & Chief Executive Officer, Jon Lieber, Chief Financial Officer, and Susan Schneider, Chief Medical Officer, will be presenting virtually at the H.C. Wainwright Global Investment Conference held May 23 - 26, 2022.

The presentation will be available to view on-demand beginning Tuesday, May 24 at 7:00 a.m. ET through the entirety of the conference and available by visiting http://ir.agtc.com/events-and-presentations.

About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies with the potential to address unmet patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with inherited retinal diseases. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3). Its preclinical programs build on the company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical needs in optogenetics, otology and CNS disorders, and has entered strategic collaborations with companies including Bionic Sight, an innovator in the emerging field of optogenetics, and retinal coding and Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. For more information, please visit https://agtc.com/.

IR/PR Contacts:
David Carey (IR)
Lazar FINN Partners
T: (212) 867-1768
david.carey@finnpartners.com

Corporate Contact:
Jonathan Lieber
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5778
jlieber@agtc.com

FAQ

What is AGTC's participation in the H.C. Wainwright Global Investment Conference?

AGTC will have its leadership team present virtually at the H.C. Wainwright Global Investment Conference from May 23 - 26, 2022.

When will AGTC's presentation be available to view?

AGTC's presentation will be available on-demand starting May 24 at 7:00 a.m. ET during the conference.

What diseases is AGTC focused on treating?

AGTC focuses on developing gene therapies for rare and debilitating inherited retinal diseases, specifically X-linked retinitis pigmentosa and achromatopsia.

What is the significance of AGTC's gene therapy programs?

AGTC's gene therapy programs are aimed at addressing significant unmet clinical needs in ophthalmology, with advanced clinical trials in inherited retinal diseases.